JOURNAL BROWSE
Search
Advanced SearchSearch Tips
HER-2 Positive Breast Cancer - a Mini-Review
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
HER-2 Positive Breast Cancer - a Mini-Review
Asif, Hafiz Muhammad; Sultana, Sabira; Ahmed, Saeed; Akhtar, Naheed; Tariq, Muhammad;
  PDF(new window)
 Abstract
Breast cancer is one of among all cancers with increased incidence, high mortality rate, and high economic and social costs. The the most common type of cancer among females worldwide, breast cancer is actually the uncontrolled proliferation of cells which attain malignancy. Recently it has shown that breast cancer contributes 11% among all types of cancer diagnosed globally on an annual basis and it is one of the leading causes of death among women. The human epidermal growth factor receptor 2 (HER-2) is a receptor tyrosine-protein kinase erbB-2 normally involved in the proliferation and division of breast cells. In some abnormal cases the HER2 gene does not work correctly and makes too many copies of itself. HER2-positive (HER2+) breast cancers constitute an aggressive type of breast cancer and tend to grow faster and are more likely to spread. However, therapies that specifically target HER2, such as Herceptin (traztuzumab), are very effective. HER2 targeted therapies, has significantly improved the therapeutic outcome for patients with HER2 positive breast cancer.
 Keywords
Breast cancer;HER2+;targeted therapy;
 Language
English
 Cited by
1.
Early Diagnosis of Breast Cancer, Sensors, 2017, 17, 7, 1572  crossref(new windwow)
2.
Targeted therapies in breast cancer: New challenges to fight against resistance, World Journal of Clinical Oncology, 2017, 8, 2, 120  crossref(new windwow)
 References
1.
Aghdash SA, Ghojazadeh M, Gareh S Sheyklo, et al (2015). Breast Cancer Screening Barriers from the Woman’s Perspective: a Meta-synthesis. Asian Pac J Cancer Prev, 16, 3463-71. crossref(new window)

2.
Albain KS, Allred DC, Clark GM (1994). Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr, 16, 35-42.

3.
Al-Dubai SA, Ganasegeran K, Alabsi AM, et al (2012). Exploration of barriers to breast-self examination among urban women in Shah Alam, Malaysia: a cross sectional study. Asian Pac J Cancer Prev, 13, 1627-32. crossref(new window)

4.
Al-Naggar RA, Bobryshev YV (2012). Practice and barriers of mammography among Malaysian women in the general population. Asian Pac J Cancer Prev, 13, 3595-600. crossref(new window)

5.
Arteaga CL, Sliwkowski MX, Osborne CK, et al (2012). Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol, 9, 16-32. crossref(new window)

6.
Asif HM, Sultana S, Akhtar N, et al (2014). Prevalence, Risk Factors and Disease Knowledge of Breast Cancer in Pakistan. Asian Pac J Cancer Prev, 15, 4411-6. crossref(new window)

7.
Azim H, Azim HA, Escudier B (2009). Trastuzumab versus lapatinib: the cardiac side of the story. Cancer Treat Rev 35, 633-8. crossref(new window)

8.
Bailey TA, Luan H, Clubb RJ, et al (2011). Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. J Carcinog, 10, 317-28.

9.
Baselga J, Albanell J, Molina MA, et al (2001). Mechanism of action of trastuzumab and scientific update. Semin Oncol, 28, 4-11. crossref(new window)

10.
Berkiten A, Sahin NH, Sahin FM, et al (2012). Meta analysis of studies about breast self examination between 2000-2009 in Turkey. Asian Pac J Cancer Prev, 13, 3389-97 crossref(new window)

11.
Blackwell KL, Burstein HJ, Storniolo AM, et al (2010). Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumabrefractory metastatic breast cancer. J Clin Oncol, 28, 1124-30. crossref(new window)

12.
Boyle P (2012). Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol, 23, 7-12. crossref(new window)

13.
Burstein HJ, Yan Sun Y, Dirix LY, et al (2010). Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol, 28, 1301-7. crossref(new window)

14.
Cameron D, Casey M, Press M, et al (2008). A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat, 112, 533-43. crossref(new window)

15.
Cetin I, Topcul (2014). M triple negative breast cancer. Asian Pac J Cancer Prev, 15, 2427-31 crossref(new window)

16.
Chibon F, de Mascarel I, Sierankowski G, et al (2009). Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations. Mod Pathol, 22, 403-409. crossref(new window)

17.
Cobleigh MA, Vogel CL, Tripathy D et al (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2- overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol, 17, 2639-48. crossref(new window)

18.
Cristofanilli M, Johnston SRD, Manikhas A, et al (2012). A randomized phase II study (VEG108838) of lapatinib plus pazopanib (L + P) versus lapatinib (L) in patients with ErbB2+ inflammatory breast cancer (IBC). ASCO Meeting Abstracts, 30, 531

19.
De Azambuja, Bedard E, Suter PL, et al (2009). Cardiac toxicity with anti HER 2 therapies: what have we learned so far? Target Oncol, 4, 39-41

20.
Fedenko K, Cortazar P, Keegan P, et al (2009). Trastuzumab cardiotoxicity: FDA review of four adjuvant breast cancer clinical trials leading to trastuzumab marketing approvals [abstract]. J Clin Oncol, 27, 11520.

21.
Floriano-Sanchez E, Rodriguez NC, Bandala C, et al (2014). CYP3A4 expression in breast cancer and its association with risk factors in Mexican women. Asian Pac J Cancer Prev, 15, 3805-9. crossref(new window)

22.
Fouladi N, Pourfarzi F, Mazaheri E, et al (2013). Beliefs and behaviors of breast cancer screening in women referring to health care centers in northwest Iran according to the champion health belief model scale. Asian Pac J Cancer Prev, 14, 6857-62 crossref(new window)

23.
Gianni L, Eiermann W Semiglazov V, et al (2014). Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, 375, 377-84.

24.
Gianni L, Dafni U, Gelber RD, et al (2011). Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4 year follow-up of a randomised controlled trial. Lancet Oncol, 12, 236-44. crossref(new window)

25.
Goldhirsch A, Wood WC, Coates AS, et al (2011). Strategies for subtypes dealing with the diversity of breast cancer: highlights of the St. gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol, 22, 1736-47. crossref(new window)

26.
Gradishar WJ (2012). HER2 therapy-an abundance of riches. N Engl J Med, 366, 176-8. crossref(new window)

27.
Graus-Porta D, Beerli RR, Daly JM, et al (1997). ErbB-2, the preferredheterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J, 16, 1647-1655. crossref(new window)

28.
Gurdal SO, Saraçoğlu VG, Oran ESO et al (2013). The Effects of Educational Level on Breast Cancer Awareness: A Cross- Sectional Study in Turkey. Asian Pac J Cancer Prev, 12, 295-300

29.
Hudis CA (2007). Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med, 357, 39-51 crossref(new window)

30.
Hui-LS, Xiao-Xin Dong, Cong YJ, et al (2015). Depression and the Risk of Breast Cancer: A Meta-Analysis of Cohort Studies. Asian Pac J Cancer Prev, 16, 3233-9. crossref(new window)

31.
Konecny GE (2006). Activity of the dual kinase inhibitor lapatinib (GW572016) against HER 2 overexpressing and trastuzumab-treated breast cancer cells. Cancer Res, 66, 42-4.

32.
Lennon S, Barton C, Banken L, et al (2009). Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol, 27, 1685-93. crossref(new window)

33.
Lewis Phillips GD, Guangmin Li, Dugger DL, et al (2008). Cancer Res, 68, 9280-90. crossref(new window)

34.
Majeed W, Aslam B, Javed I, et al (2014). Breast cancer: major risk factors and recent developments in treatment. Asian Pac J Cancer Prev, 15, 3353-8. crossref(new window)

35.
Marty M, Cognetti F, Maraninchi D, et al (2005). Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol, 23, 4265-74. crossref(new window)

36.
Mayer IA, Arteaga CL (2010). Does lapatinib work against HER2-negative breast cancers? Clin Cancer Res, 16, 1355-7. crossref(new window)

37.
Molina MA, Codony-Servat J, Albanell J, et al (2001). Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res, 61, 4744-9.

38.
National Comprehensive Cancer Network NCCN Practice Guidelines in Oncology. National Comprehensive Cancer Network [online] http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf (2011).

39.
Erbil N, Bolukbas N (2012) Health beliefs and breast selfexamination among female university nursing students in Turkey. Asian Pac J Cancer Prev, 15, 6525-6529.

40.
O Donovan N, Byrne AT, O Connor AE, et al (2011). Synergistic interaction between trastuzumab and EGFR/HER 2 tyrosine kinase inhibitors in HER 2 positive breast cancer cells. Invest. New Drugs, 29, 752-759. crossref(new window)

41.
Perez EA, Koehler M, Byrne J et al (2008). Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc, 83, 679-686. crossref(new window)

42.
Qi Yang, Hong-Yan Liu, Dan Liu, et al (2015). Ultrasonographic features of triple-negative breast cancer: a comparison with other breast cancer subtype. Asian Pac J Cancer Prev, 16, 3229-32. crossref(new window)

43.
Rabindran SK, Discafani CM, Rosfjord EC (2004). Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res, 64, 3958-65. crossref(new window)

44.
Rimawi MF, Aleixo SB, Alarcon RA, et al (2012). A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC). ASCO Meeting Abstracts, 30, 606.

45.
Ross JS, Fletcher JA (1998). The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Oncologist, 3, 237-252.

46.
Rubin I, Yarden Y (2001). The basic biology of HER2. Ann Oncol, 12, 13-8.

47.
Sauter G, Lee J, Bartlett JM, et al (2009). Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol, 27, 1323-33. crossref(new window)

48.
Slamon DJ, Leyland-Jones B, Shak S, et al (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 783-92. crossref(new window)

49.
Spector NL, Blackwell KL (2009). Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2 positive breast cancer. J Clin Oncol, 27, 5838-47. crossref(new window)

50.
Spector NL, Xia W, Burris H, et al (2005). Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol, 23, 2502-12. crossref(new window)

51.
Tubbs R, Barlow WE, Budd GT, et al (2009). Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol, 27, 3881-3886. crossref(new window)

52.
Untch M, Muscholl M, Tjulandin S, et al (2010). First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. J Clin Oncol, 28, 1473-80. crossref(new window)

53.
Von Minckwitz, G du Bois A, Schmidt M, et al (2009). Trastuzumab beyond progression in human epidermal growth factor receptor 2 positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol, 27, 1999-2006. crossref(new window)

54.
Wardley AM, Xavier Pivot, Flavia MV, et al (2010). Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol, 28, 976-83. crossref(new window)

55.
Wolff AC, Hammond ME, Hicks DG, et al. (2013). J Clin Oncol, 31, 3997-4013. crossref(new window)

56.
Wolff AC, Hammond ME, Schwartz JN, et al (2007). American society of clinical oncology; college of american pathologists. american society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 25, 118-45.

57.
Xia, W, Liu LH, Ho P, Spector NL (2004). Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene, 23, 646-53. crossref(new window)

58.
Xiu-Juan, Zha Q, Xin XY, et al (2014). Lack of Prognostic Value of Human Epidermal Growth Factor-Like Receptor 2 Status in Inflammatory Breast Cancer (IBC): a Meta-analysis. Asian Pac J Cancer Prev, 15, 9615-9. crossref(new window)

59.
Yardley DA, Burris HA, Hanson S, et al (2009). Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer, 9, 178-83. crossref(new window)

60.
Yerushalmi R, Gelmon K (2010). Treatment beyond progression: is it moving from belief to evidence? Oncologist, 15, 796-8. crossref(new window)

61.
Yin W, Jiang Y, Shen Z, et al (2011). Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS One, 6, 21030. crossref(new window)

62.
Yusuf A, Ab Hadi IS, Mahamood Z, et al (2013). Understanding the breast cancer experience: a qualitative study of Malaysian women. Asian Pac J Cancer Prev, 14, 3689-98. crossref(new window)

63.
Zainal NZ, Nik-Jaafar NR, Baharudin A, et al (2013). Prevalence of depression in breast cancer survivors: a systematic review of observational studies. Asian Pac J Cancer Prev, 14, 2649-56. crossref(new window)

64.
Zubeda S, Kaipa PR, Shaik NA (2013). HER-2/neu status: a neglected marker of prognostication and management of breast cancer patients in India. Asian Pac J Cancer Prev, 14, 2231-5. crossref(new window)